Source: Eur Respir J 2014; 43: 292-294
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
van Halsema Clare, Humphreys Susan, Bonington Alec. Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient. Eur Respir J 2014; 43: 292-294

Member's Comments

No comment yet.

Related content which might interest you: Early access to bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis Source: Eur Respir J, 54 (1) 1802208; 10.1183/13993003.02208-2018 Year: 2019 Extensively drug-resistant tuberculosis: back to the future Source: Eur Respir J 2010; 36: 475-477 Year: 2010 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012 Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016 Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB): a retrospective comparative study Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India Source: Eur Respir J , 49 (3) 1601699; DOI: 10.1183/13993003.01699-2016 Year: 2017 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Genotypes and drug resistance patterns of multi-drug-resistant mycobacterium tuberculosis strains in Pakistan Source: International Congress 2015 – Non-tuberculous mycobacteria and molecular microbiology Year: 2015 The MTBDRplus 2.0 for rapid diagnosis of multidrug-resistant tuberculosis among patients with high risk of TB resistance Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Multidrug-resistant tuberculosis in UK children: presentation, management and outcome Source: Eur Respir J 2013; 41: 1456-1458 Year: 2013 Extensively drug-resistant (XDR) pulmonary tuberculosis in HIV negative cases Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Extensively drug-resistant tuberculosis (XDR-TB) treatment outcome. Cohort study Source: Annual Congress 2010 - Multidrug-resistant and extensively drug-resistant tuberculosis Year: 2010 Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003